Dapagliflozin for Long COVID Syndrome

Sponsor
Ottawa Heart Institute Research Corporation
Study ID
NCT06907251
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • COVID - 19
  • Long COVID Syndrome
  • SARS CoV-2

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin (DAPA) — DRUG
    Dapagliflozin 10mg orally once a day for 12 months
  • Placebo — DRUG
    Participants will receive a matching placebo taken once daily by mouth for 12 months.

Study Details

This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.

Key Dates

Start date
Apr 1, 2026
Status verified
Apr 2026
Primary completion
Jun 30, 2028
Completion
Jun 30, 2029

Study Design

Enrollment
192 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Interventional
    Participants will receive 10mg dapagliflozin orally for 12 months
  • Placebo Comparator: Placebo
    Participants will receive a placebo once daily for 12 months.

Primary Outcome Measure

6 month change in EQ-5D derived utility score. [ Time Frame: 6 months ]

Central Contacts

Related Studies